Tavo Biotherapeutics

Executive Summary

Tavo Biotherapeutics is a private, early-stage biotechnology company headquartered in Houston, Texas, focused on developing next-generation T-cell immunotherapies and antibody-based treatments for oncology and autoimmune diseases. Founded in 2019, the company aims to harness the immune system to target solid tumors and autoimmune disorders through novel cell therapy and bispecific antibody platforms. Tavo's approach leverages proprietary engineering of T-cell receptors and antibody fragments to enhance tumor infiltration, reduce off-target toxicity, and improve persistence in the tumor microenvironment. In autoimmune indications, the company is exploring T-cell modulation to restore immune tolerance without broad immunosuppression. While still in the preclinical to Phase 1 stage, Tavo has not disclosed its total funding or valuation, suggesting an early development phase. The company's small size (10–50 employees) and lack of public pipeline details indicate a focus on research and initial clinical validation. Given the competitive landscape in cell therapy and the high technical risk associated with novel platforms, Tavo's success hinges on generating compelling proof-of-concept data in upcoming clinical trials. The company's ability to secure partnerships or additional financing will be critical to advancing its programs through early clinical development.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 clinical trial initiation for lead oncology T-cell therapy candidate35% success
• Q4 2026IND filing for autoimmune disease antibody-based therapy30% success
• Q3 2026Series A financing round or strategic partnership announcement50% success